Universal Library of Business and Economics Research Article

ISSN: 3064-9951 | Volume 3, Issue 3

Open Access | PP: 01-06

DOI: https://doi.org/10.70315/uloap.ulbec.2026.0303001

Impact of No-Code AI Drug Discovery Platforms on the Operational Cost Structure of Biotechnology Ventures

Timotej Szalay

Founder and Chief Executive Officer, ABYA Genomics, Slovakia.

Abstract

Biotechnology ventures face high uncertainty before their programs reach laboratory validation, while early spending decisions shape runway, financing options, and the pace of evidence formation. This review examines how no-code AI drug discovery platforms affect the operating cost structure of early-stage biotechnology ventures. The purpose is to connect in silico discovery workflows with burn-rate planning, time-to-value, and valuation inflection points. The source base contained recent scholarly and industry publications on drug development costs, venture investment, AI-assisted discovery, generative design, multimodal biomedical data, cloud deployment, and no-code drug-discovery tools. The review used comparative source analysis, conceptual synthesis, classification, and analytical generalization. The results identify a cost migration from fixed laboratory commitments toward cloud compute, data work, platform access, model governance, and staged validation. Practical value lies in a management framework that links computational discovery spending to evidence gates, financing decisions, and delayed laboratory buildout.

Keywords: *No-Code AI, Drug Discovery, Biotechnology Ventures, Operational Cost Structure, CAPEX, OPEX, In Silico Discovery, Cloud Infrastructure, Burn Rate.*

INTRODUCTION

Early-stage biotechnology ventures enter discovery under a timing constraint that differs from ordinary software entrepreneurship. A scientific hypothesis needs biological validation, yet cash has to cover salaries, data, assays, external services, platform access, laboratory capacity, and investor communication before a candidate reaches a proof point. A founder who commits too much capital to internal laboratory infrastructure at the start reduces the room for hypothesis revision. A founder who delays validation for too long weakens credibility with investors and partners.

No-code AI drug discovery platforms sit inside this managerial tension. Research teams use them to run computational screening, target prioritization, sequence analysis, molecular design, and candidate ranking through product interfaces that reduce dependence on custom software development for each exploratory step. The economic question concerns the sequence of spending. The venture can shift part of the early discovery work into cloud compute, software subscriptions, curated datasets, and model-supported workflows before purchasing broad wet-lab capacity. The article aims to examine how no-code AI drug discovery platforms affect the operational cost structure of biotechnology ventures. The first research objective is to define the baseline cost logic of early biotechnology ventures under asset-heavy discovery. The second objective is to identify how AI-enabled and no-code discovery workflows redistribute costs, uncertainty, and managerial control across preclinical work. The third objective is to formulate a management framework that connects cost migration with burn rate, time-to-value, and valuation inflection points.

The novelty of the article lies in treating no-code AI drug discovery platforms as a management instrument for early-stage capital allocation. The article connects technical abstraction, cost classification, and venture survival metrics within a single analytical frame. The hypothesis states that a shift from early wet-lab commitments toward no-code AI and cloud-based discovery improves capital flexibility and accelerates the formation of financeable evidence when management links computational outputs to validation gates, data governance, and spending controls.

MATERIALS AND METHODS

The review drew on sources published from 2023 to 2026, with one industry report included because cloud deployment and procurement patterns are directly relevant

Citation: Timotej Szalay, "Impact of No-Code AI Drug Discovery Platforms on the Operational Cost Structure of Biotechnology Ventures", Universal Library of Business and Economics, 2026; 3(3): 01-06. DOI: https://doi.org/10.70315/uloap.ulbec.2026.0303001.

to the article's economic angle. The source base covered four groups of questions: drug-development cost and R&D intensity [9], venture-capital investment in AI-driven biopharmaceutical startups [1], AI methods across drug discovery and development [3–6; 10], and platform-level issues connected with multimodal biomedical data, cloud deployment, and no-code tools [2; 7; 8]. The screening selected peer-reviewed reviews, economic evaluations, empirical investment research, and an industry report. The screening excluded vendor promotion without analytical content, general digital health publications without therapy-discovery relevance, and publications lacking transparent bibliographic data. No proprietary financial or technical data from any startup entered the material base.

The review used comparative analysis to distinguish asset-heavy and AI-supported cost structures. Source analysis linked published evidence to the three research objectives. Conceptual synthesis formed the management framework. Classification separated cost categories, evidence gates, and survival metrics. Analytical generalization converted the source findings into a venture-level operating logic without claiming experimental validation.

RESULTS

The baseline cost structure of a biotechnology venture begins with an imbalance between uncertainty and spending rigidity. Sertkaya et al. estimate the mean cash outlay for developing a new drug for the U.S. market at $172.7 million in 2018 dollars, rising to $515.8 million after failure costs and to $879.3 million after failure and capital costs [9]. The figure's relevance for early ventures lies in the mechanism behind the number. Capital tied to long development cycles creates a financing burden before the team knows which candidate deserves further work.

This cost pattern pressures small ventures earlier than it pressures mature pharmaceutical firms. A large company spreads failed programs across portfolios, revenue streams, and internal infrastructure. A young venture has a narrower runway and fewer parallel assets. If management commits early cash to facilities, equipment, and permanent capacity, the venture inherits a monthly spending floor that remains even after a hypothesis weakens. Cost then ceases to be a record of past activity and becomes a constraint on future choices.

AI-driven biopharmaceutical startups have attracted investor attention because computational discovery is now a financeable business category. Bazaz et al. analyze venture capital trends in AI-driven biopharmaceutical startups from 2010 to 2024 and identify rapid growth in investment in discovery tools [1]. This evidence shows that investors are beginning to treat discovery tools, computational infrastructure, and AI-enabled research workflows as legitimate venture assets. For no-code drug discovery, this point matters because valuation conversations can begin before the full internal laboratory buildout if the venture produces evidence that investors can assess.

Technical reviews explain why investors and founders pay attention to AI-assisted discovery. Recent reviews describe AI applications in target identification, virtual screening, de novo molecular design, QSAR and QSPR modeling, ADMET prediction, lead optimization, and clinical development support [3; 4; 6; 10]. These applications shift part of the search process into computational pre-selection. The venture still needs biological validation. The operational change appears earlier: the team can reduce the candidate space before spending on broader wet-lab testing.

Generative AI adds another cost implication. Reviews of generative models in drug discovery describe their use in de novo molecular design and candidate generation [5]. A venture using these tools can explore chemical or biological design spaces before ordering full experimental work. The managerial value depends on filtering. A large set of model-generated candidates increases downstream burden if the team lacks ranking rules, toxicity filters, synthesis constraints, and validation budgets. Generative output gains economic meaning only when management turns it into a smaller set of candidates with documented reasons for selection.

Multimodal AI extends this logic beyond single-input modeling. Bhushan and Misra discuss multimodal AI across biotechnology and digital medicine, including applications that combine data types relevant to drug discovery, genomics, and personalized medicine [2]. A no-code discovery workflow may require genomic records, phenotypic data, molecular structures, assay results, and literature-derived evidence. Spending therefore moves toward data ingestion, annotation, cleaning, storage, provenance tracking, and secure processing. These cost items fall under operating expenditure, but they serve as the basis for later validation decisions.

Nizhenkovska et al. compare AI-driven no-code applications for drug discovery and development based on ease of use, interface design, user experience, speed, resource use, accuracy, and scalability [8]. The reported differences across platforms warn against treating a simple interface as proof of economic efficiency. A venture may reduce dependence on custom coding for routine exploratory work, while still facing compute cost, platform variance, accuracy limits, and scalability constraints.

A comparison of technical reviews and the no-code platform study gives a more precise conclusion. Reviews of AI in drug discovery report broad use across target selection, screening, and design [3; 4; 6; 10]. The no-code comparison reports variation in usability, predictive accuracy, computational demand, and scalability across selected applications [8]. Generative AI reviews add model-specific constraints

around training data, validation and practical translation [5]. Together, these sources support a managerial interpretation: no-code AI changes the timing and classification of costs. At the same time, experimental validation and data-quality control remain part of the venture's cost base.

Market evidence points in the same direction from the procurement side. MarketsandMarkets reports cloud deployment as a major segment in the AI drug-discovery market [7]. Since industry forecasts carry commercial assumptions, the article uses this source only to frame deployment patterns. Cloud deployment affects cost classification. Teams pay for compute, storage, subscriptions, APIs, security, and data operations through usage or service contracts. These costs still reduce cash, but management can tie them to narrower work packages than laboratory leases or proprietary equipment.

Figure 1 presents the cost migration in venture-management terms. The figure adapts pipeline logic from AI drug-development reviews and cloud-deployment evidence from the industry source [7; 10].



Figure 1. Operating-cost migration in an AI-supported drug-discovery venture. Adapted from AI drug-development pipeline logic [10] and cloud deployment evidence in AI drug discovery [7].

In a wet-lab-first pathway, management buys capacity before the team has narrowed the hypothesis space. In a no-code AI and cloud-first pathway, management funds data work, compute, platform access, and candidate ranking before broad experimental spending. The venture still pays for validation, but it pays after a narrower decision gate.

The predictive management frame follows from this ordering. The venture begins with available runway, baseline salary costs, data costs, platform costs, compute costs, validation reserves, and any fixed laboratory commitments. Management assigns discovery activity to three zones: computational exploration, targeted validation, and durable buildout. Computational exploration covers target prioritization, in silico screening, generative design, and hypothesis ranking. Targeted validation covers assays, external laboratory work, contract research, and reproducibility checks. Durable buildout covers internal wet-lab equipment, leases, and permanent specialist hiring.

Time-to-value in this frame means the earliest point at which the venture holds an evidence package strong enough for a financing, partnership, or internal go/no-go decision. The package needs a reproducible target rationale, a ranked candidate class, documented data lineage, preliminary safety filters, a planned assay design, and a validation budget. Valuation inflection points arise when investors or partners update financing terms after such evidence reduces uncertainty.

Burn-rate planning changes under this frame. A wet-lab-heavy structure creates a high monthly floor after management commits to facilities, instruments, and internal capacity. A no-code AI structure shifts part of that floor into workload-based expenditure. Compute runs, platform seats, storage, external datasets, and validation orders still require control. Their advantage lies in narrower stop rules. If a target family fails a computational plausibility threshold, management can cancel the next run or validation order before expanding laboratory commitments.

This cost migration creates a new risk pattern. A low-friction interface may increase the number of exploratory runs, hypotheses, and candidate designs. The venture may avoid a visible equipment purchase while accumulating cloud charges, subscriptions, data-cleaning labor, and repeated validation requests. Nizhenkovska et al. report variation in resource use and scalability across no-code applications [8]. Management has to treat OPEX as a controlled discovery budget.

The first research objective leads to a clear baseline finding. Asset-heavy discovery exposes a young venture to fixed costs before biological uncertainty has narrowed enough for confident capital allocation. The second objective leads to a redistribution finding. No-code AI and cloud workflows move part of early discovery into operating expenditure tied to data, compute, platform use, and model governance. The third objective leads to a management finding. Venture survival improves only when computational spending produces evidence gates that guide financing, validation, and laboratory buildout.

DISCUSSION

A practical operating model should begin with the evidence threshold. Management first defines which decision the next discovery cycle must support: target continuation, candidate narrowing, validation entry, financing preparation, or partnership discussion. The team then assigns a budget ceiling to that decision. This sequence prevents the platform from becoming a general exploration environment without spending boundaries.

The next step concerns data. The team documents data sources, cleaning procedures, annotation rules, and exclusion criteria before model development begins. A no-code interface may reduce coding burden, but it cannot replace data discipline. Poor input quality shifts costs to later corrections, repeated computation, and weak validation results. For this reason, a data-readiness review should be conducted before each major computational cycle.

Platform adoption should follow a staged contract logic. A young venture benefits from short commitments, export rights, transparent pricing, workload caps, and clear rules for model-version changes. These terms protect management from vendor lock-in before the platform has produced repeated decision-grade outputs. A financial dashboard should record platform seats, compute use, storage, data purchase, external validation orders, and salary allocation by hypothesis family. Cost visibility at this level gives management a way to compare programs before cash pressure forces broad cuts.

Table 1 compares the decision logic under asset-heavy discovery and no-code AI-supported discovery. The purpose is to show which management decision changes at each spending point and how CAPEX migration into OPEX should be governed.

Table 1. Decision logic for shifting early discovery expenditure from CAPEX to OPEX

Decision domain	Asset-heavy wet-lab pattern	No-code AI and cloud pattern	Management rule
Initial infrastructure	Laboratory access, equipment, and internal assay capacity	Platform access, cloud compute, and data workspace	Approve the fixed laboratory buildout after a ranked hypothesis set exists
Discovery search	Broad experimental screening	Computational prioritization before targeted validation	Fund a broader search only within a pre-set cost ceiling per hypothesis family
Talent structure	Early permanent hiring across laboratory and computational functions	Smaller core team with platform-mediated workflows and external validation partners	Add permanent specialists after repeated validated demand appears
Spending flexibility	High monthly floor after laboratory commitments	Adjustable software, compute, and validation orders	Link each OPEX increase to an evidence threshold
Failure response	Slow reduction of fixed commitments	Faster cancellation of weak hypothesis lines	Stop weak lines before the validation cost expands
Investor evidence	Laboratory activity as a proxy for progress	Documented computational evidence with a validation plan	Present evidence packages during financing discussions

The table frames no-code AI as a spending-sequence tool. The venture still needs laboratory validation, scientific judgment, and regulatory preparation. The change lies in the order of capital exposure. Management buys computational optionality first, targeted evidence second, and durable infrastructure after repeated demand justifies it. If the team skips evidence gates, no-code AI turns into a faster route to weak leads and scattered spending.

Monitoring needs to connect cash burn with decision quality. Monthly burn tells the board how long the company can operate. It does not tell the board whether spending has produced evidence that changes the next financing or validation decision. Table 2 proposes a monitoring set for operating reviews, board meetings, and investor preparation.

Table 2. Monitoring metrics for an AI-virtualized drug-discovery venture

Metric	Operational meaning	Measurement cadence	Corrective trigger
Runway per validated decision	Months of cash available for each completed evidence gate	Monthly	Fewer completed gates per month of burn
Cost per ranked hypothesis	Platform, compute, and data costs are divided by hypotheses passing the ranking criteria	Per discovery cycle	Rising cost without stronger validation readiness
Validation conversion ratio	Share of computational candidates entering targeted wet-lab validation	Per program gate	Too many candidates enter validation without a clear priority
Compute budget variance	The difference between planned and actual computer expenditure	Weekly during active runs	Repeated overrun or unclear workload driver
Data-readiness score	Completeness, provenance, and quality of input data	Before each model cycle	Missing lineage, inconsistent annotation, or undocumented cleaning

Evidence package maturity	Degree to which outputs meet financing or partnership evidence thresholds	Before financing milestones	Heavy platform activity with weak decision records
Vendor dependency exposure	Reliance on one platform, model, or data pipeline	Quarterly	No export path, opaque versioning, or pricing lock-in
Wet-lab commitment ratio	Share of discovery spend committed to laboratory work	Monthly	Laboratory spend rises before computational gates close

A high number of runs may signal curiosity, poor prioritization, or unclear thresholds. A lower number of runs tied to a mature evidence package may serve the venture better. Board discussions should therefore focus on cost per validated decision, validation conversion, and evidence maturity.

The operating sequence has five steps. Management defines the biological question and the financing evidence threshold. The team prepares data with documented provenance and quality grading. Researchers use the no-code platform for screening, design and ranking under a pre-approved compute budget. Candidates that pass ranking and documentation thresholds move into targeted validation. Management updates the runway, valuation narrative, and laboratory buildout plans after validation results are received.

This sequence requires founder discipline. No-code access lowers the barrier to exploration, and lower friction can increase poorly bounded work. The team should separate interface simplicity from scientific accountability. A simple workflow should sit above strict version control, reproducibility checks, budget tags, and validation records. Scientists, product leads, and finance managers need a shared definition of a completed evidence gate.

Investors rarely price computational activity by itself but they reduce price uncertainty. A defensible milestone states that the team generated a ranked candidate set from documented data, removed candidates that failed specified filters, selected a validation cohort, and produced results strong enough to justify the next spending stage. This framing connects the platform to risk reduction and gives the investor a clearer basis for financing terms.

CAPEX planning should follow repeated validated demand. Internal laboratory capacity may be needed after the venture sees recurring validation needs, predictable assay types, and high external service costs. Before that point, contract research, shared facilities, and academic partnerships preserve cash flexibility. Durable buildout becomes rational when external validation creates delays, cost leakage, or operational risks that internal capacity can reduce.

The management position is cautious but favorable. No-code AI platforms deserve a place in early biotechnology operating models because they help teams stage discovery expenditure. They help management decide which expensive steps deserve funding and in what order. The economic value of the platform depends on evidence gates.

CONCLUSION

No-code AI drug discovery platforms shift part of early discovery spending from fixed wet-lab commitments toward cloud compute, platform access, data preparation, model governance, and targeted validation planning. This shift reduces early capital irreversibility and gives biotechnology ventures more time to test hypotheses before committing to a durable laboratory buildout.

Venture survival metrics improve only when management ties computational work to decision-grade evidence. Time-to-value moves earlier when the team produces a documented package that supports financing, partnership, or go/no-go decisions. Valuation inflection points move earlier when investors or partners see reproducible reductions in uncertainty.

The hypothesis receives support within the limits of a review-based study. No-code AI and cloud infrastructure improve early-stage capital flexibility by linking OPEX growth to validation gates, runway monitoring, and evidence maturity. The appropriate sequence is computational search, targeted validation, and then a fixed laboratory buildout after repeated evidence demands.

REFERENCES

1. Bazaz, A., Ji, Y., Socal, M. P., & Kang, S. Y. (2026). Trends in venture capital investment in AI-driven biopharmaceutical startups. Journal of Medical Internet Research, 28, e84968. https://doi.org/10.2196/84968
2. Bhushan, A., & Misra, P. (2025). Unlocking the potential: Multimodal AI in biotechnology and digital medicine, economic impact and ethical challenges. npj Digital Medicine, 8, 619. https://doi.org/10.1038/s41746-025-01992-6
3. Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023). The role of AI in drug discovery: Challenges, opportunities, and strategies. Pharmaceuticals, 16(6), 891. https://doi.org/10.3390/ph16060891
4. Ferreira, F. J. N., & Carneiro, A. S. (2025). AI-driven drug discovery: A comprehensive review. ACS Omega, 10(23), 23889-23903. https://doi.org/10.1021/acsomega.5c00549
5. Gangwal, A., Lavecchia, A., & Rani, M. (2024). Generative

artificial intelligence in drug discovery: Basic framework, recent advances, challenges, and opportunities. Frontiers in Pharmacology, 15, 1331062. https://doi.org/10.3389/fphar.2024.1331062

6. Khan, M. K., Raza, M., Shahbaz, M., Hussain, I., Khan, M. F., Xie, Z., Shah, S. S. A., Tareen, A. K., Bashir, Z., & Khan, K. (2024). The recent advances in the approach of artificial intelligence toward drug discovery. Frontiers in Chemistry, 12, 1408740. https://doi.org/10.3389/fchem.2024.1408740
7. MarketsandMarkets. (2024). AI in drug discovery market by offering, process, therapeutic area, end user, deployment mode and region: Global forecast to 2029. https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html
8. Nizhenkovska, I., Reva, T., Kuznetsova, O., Nizhenkovskyi, O., & Chkhalo, O. (2024). A comparison study of artificial intelligence-driven no-code applications for drug discovery and development. ScienceRise: Pharmaceutical Science, 6(52), 80-89. https://doi.org/10.15587/2519-4852.2024.318920
9. Sertkaya, A., Beleche, T., Jessup, A., & Sommers, B. D. (2024). Costs of drug development and research and development intensity in the US, 2000-2018. JAMA Network Open, 7(6), e2415445. https://doi.org/10.1001/jamanetworkopen.2024.15445
10. Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., Li, X., Wu, J. C., & Yang, S. (2025). Artificial intelligence in drug development. Nature Medicine, 31(1), 45-59. https://doi.org/10.1038/s41591-024-03434-4